Literature DB >> 20140350

Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008).

Ana C Gales1, Helio S Sader, Julival Ribeiro, Cassia Zoccoli, Afonso Barth, Antonio C Pignatari.   

Abstract

We report the antimicrobial susceptibility patterns of the most frequently isolated Gram-positive bacteria in the Brazilian hospitals participating in the SENTRY Antimicrobial Surveillance Program. The strains were consecutively collected (one per patient) between January 2005 and September 2008 and susceptibility tested by reference broth microdilution methods at the JMI Laboratories (North Liberty, Iowa, USA). A total of 3,907 Gram-positive cocci were analyzed. The Gram-positive organisms most frequently isolated from bloodstream infections were Staphylococcus aureus (2,218 strains; 20.2% of total), coagulase-negative staphylococci (CoNS; 812 strains [14.7%]), and Enterococcus spp. (754 strains; 5.0%). S. aureus ranked first (28.1%) and Enterococcus faecalis ranked 7th (4.5%) among cases of skin and soft tissue infections. S. aureus was also the second most frequently isolated pathogen from patients with lower respiratory tract infections (24.9% of cases) after Pseudomonas aeruginosa (30.5%). Resistance to oxacillin was observed in 31.0% of S. aureus and the vast majority of oxacillin-resistant (MRSA) strains were also resistant to clindamycin, ciprofloxacin and levofloxacin. Vancomycin, linezolid and daptomycin were all very active against S. aureus strains tested (>99.9-100.0% susceptible), but daptomycin (MIC(50), 0.25 g/mL and MIC(90), 0.5 g/mL) was four- to eight-fold more potent than vancomycin (MIC(50) and MIC(90) of 1 g/mL) and linezolid (MIC(50), 1 g/mL and MIC(90), 2 g/mL). Vancomycin resistance increased significantly among enterococci during the study period, but it was restrict to only one medical center until 2007 and emerged in a second medical center in 2008. Daptomycin was the most active antimicrobial tested against enterococci in general (100.0% susceptible), followed by linezolid (99.9% susceptible), ampicillin (87.4%) and vancomycin (84.6%). In conclusion, daptomycin and linezolid showed excellent in vitro activity against contemporary Gram-positive organisms (3,907) collected in Brazilian hospitals monitored by the SENTRY Program, including MRSA, vancomycin-resistant enterococci (VRE) and other multi-drug-resistant organisms. Although vancomycin resistance rates in Brazil appears to be relatively low compared to those reported in the USA, VRE has emerged and rapidly disseminated in some Brazilian medical centers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20140350     DOI: 10.1590/s1413-86702009000200004

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  26 in total

1.  Controlling a vancomycin-resistant enterococci outbreak in a Brazilian teaching hospital.

Authors:  M L Moretti; L G de Oliveira Cardoso; C E Levy; A Von Nowakosky; L F Bachur; O Bratfich; M L Leichsenring; R Fagnani; S M Peres Evangelista Dantas; M R Resende; P Trabasso
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-24       Impact factor: 3.267

2.  Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.

Authors:  Rodrigo M Paiva; Alice B Mombach Pinheiro Machado; Alexandre P Zavascki; Afonso L Barth
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

3.  Antimicrobial Susceptibility and Enterotoxin-Encoding Genes in Staphylococcus spp. Recovered from Kitchen Equipment from a University Hospital in Rio de Janeiro, Brazil.

Authors:  Roberta Fontanive Miyahira; Emanoella Araújo Santos; Robson Souza Leão; Angela Corrêa de Freitas-Almeida; Mara Lucia Queiroz
Journal:  Microb Drug Resist       Date:  2018-03-20       Impact factor: 3.431

4.  Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.

Authors:  Julianne Kim; Sandra A N Walker; Dolores C Iaboni; Scott E Walker; Marion Elligsen; Michael S Dunn; Vanessa G Allen; Andrew Simor
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

5.  Evaluation of antibacterial activity, phytochemical constituents, and cytotoxicity effects of Thai household ancient remedies.

Authors:  Sasitorn Chusri; Naruephan Sinvaraphan; Ploypailin Chaipak; Atita Luxsananuwong; Supayang Piyawan Voravuthikunchai
Journal:  J Altern Complement Med       Date:  2014-12       Impact factor: 2.579

6.  The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia.

Authors:  Denise Pires Machado; Luciano Z Goldani; Rodrigo Minuto Paiva; Valério Rodrigues Aquino; Fernanda de-Paris; Thiago Lisboa; Bruno Jung; Rodrigo Pires Dos Santos
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 7.  Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.

Authors:  Bhavarth S Shukla; Timothy P Gauthier; Ricardo Correa; Laura Smith; Lilian Abbo
Journal:  Int J Clin Pharm       Date:  2013-07-27

8.  The need for continued monitoring of antibiotic resistance patterns in clinical isolates of Staphylococcus aureus from London and Malta.

Authors:  Simon W J Gould; Paul Cuschieri; Jess Rollason; Anthony C Hilton; Sue Easmon; Mark D Fielder
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-07-21       Impact factor: 3.944

9.  Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.

Authors:  Beth White; R Andrew Seaton
Journal:  Infect Drug Resist       Date:  2011-05-24       Impact factor: 4.003

10.  Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.

Authors:  Michael Zoller; Barbara Maier; Cyrill Hornuss; Christina Neugebauer; Gundula Döbbeler; Dorothea Nagel; Lesca Miriam Holdt; Mathias Bruegel; Thomas Weig; Béatrice Grabein; Lorenz Frey; Daniel Teupser; Michael Vogeser; Johannes Zander
Journal:  Crit Care       Date:  2014-07-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.